A comparison of epithelial membrane antigen overexpression in benign malignant endometrium

Pluvio J. Coronado; Maria Fasero; Jose A. Vidart; Javier Puerta; Javier Magrina; Vicente Furio-Bacete; Manuel Escudero

doi:10.1006/gyno.2001.6283

A comparison of epithelial membrane antigen overexpression in benign malignant endometrium

Pluvio J. Coronado, Maria Fasero, Jose A. Vidart, Javier Puerta, Javier Magrina, Vicente Furio-Bacete, Manuel Escudero

Medical and Surgical Gynecology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Objective. The aim of this study was to analyze the value of epithelial membrane antigen (EMA) overexpression in benign and malignant endometrium and its prognostic significance. Methods. EMA immunostaining was performed in 178 paraffin-embedded specimens including 105 endometrial cancers, 40 endometrial hyperplasias, and 33 benign endometriums. EMA immunostaining was correlated with traditional prognostic factors and progression-free survival in endometrial cancer specimens. Results. EMA overexpression was observed more frequently in adenocarcinomas (60%) than in hyperplasias (15%) or benign endometrium (9.1%). EMA overexpression was observed in two patients with endometrial hyperplasia who progressed to carcinoma. In adenocarcinomas, EMA overexpression had a positive correlation with nonendometrioid subtypes (P = 0.012). In multivariate analysis, FIGO stage (P = 0.025) and EMA overexpression (P = 0.017) were independent prognostic factors for progression-free survival. Conclusions. EMA overexpression appears to be a marker of malignant transformation in the endometrium and it is an independent predictor of recurrent disease in endometrial cancer.

Original language	English (US)
Pages (from-to)	483-488
Number of pages	6
Journal	Gynecologic oncology
Volume	82
Issue number	3
DOIs	https://doi.org/10.1006/gyno.2001.6283
State	Published - Jan 1 2001

Keywords

Endometrial cancer
Epithelial membrane antigen
Prognostic factors
Recurrence
Survival

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1006/gyno.2001.6283

Cite this

@article{60b922b1a1d94b50a0edc1133cbb39d2,

title = "A comparison of epithelial membrane antigen overexpression in benign malignant endometrium",

abstract = "Objective. The aim of this study was to analyze the value of epithelial membrane antigen (EMA) overexpression in benign and malignant endometrium and its prognostic significance. Methods. EMA immunostaining was performed in 178 paraffin-embedded specimens including 105 endometrial cancers, 40 endometrial hyperplasias, and 33 benign endometriums. EMA immunostaining was correlated with traditional prognostic factors and progression-free survival in endometrial cancer specimens. Results. EMA overexpression was observed more frequently in adenocarcinomas (60%) than in hyperplasias (15%) or benign endometrium (9.1%). EMA overexpression was observed in two patients with endometrial hyperplasia who progressed to carcinoma. In adenocarcinomas, EMA overexpression had a positive correlation with nonendometrioid subtypes (P = 0.012). In multivariate analysis, FIGO stage (P = 0.025) and EMA overexpression (P = 0.017) were independent prognostic factors for progression-free survival. Conclusions. EMA overexpression appears to be a marker of malignant transformation in the endometrium and it is an independent predictor of recurrent disease in endometrial cancer.",

keywords = "Endometrial cancer, Epithelial membrane antigen, Prognostic factors, Recurrence, Survival",

author = "Coronado, {Pluvio J.} and Maria Fasero and Vidart, {Jose A.} and Javier Puerta and Javier Magrina and Vicente Furio-Bacete and Manuel Escudero",

year = "2001",

month = jan,

day = "1",

doi = "10.1006/gyno.2001.6283",

language = "English (US)",

volume = "82",

pages = "483--488",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - A comparison of epithelial membrane antigen overexpression in benign malignant endometrium

AU - Coronado, Pluvio J.

AU - Fasero, Maria

AU - Vidart, Jose A.

AU - Puerta, Javier

AU - Magrina, Javier

AU - Furio-Bacete, Vicente

AU - Escudero, Manuel

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Objective. The aim of this study was to analyze the value of epithelial membrane antigen (EMA) overexpression in benign and malignant endometrium and its prognostic significance. Methods. EMA immunostaining was performed in 178 paraffin-embedded specimens including 105 endometrial cancers, 40 endometrial hyperplasias, and 33 benign endometriums. EMA immunostaining was correlated with traditional prognostic factors and progression-free survival in endometrial cancer specimens. Results. EMA overexpression was observed more frequently in adenocarcinomas (60%) than in hyperplasias (15%) or benign endometrium (9.1%). EMA overexpression was observed in two patients with endometrial hyperplasia who progressed to carcinoma. In adenocarcinomas, EMA overexpression had a positive correlation with nonendometrioid subtypes (P = 0.012). In multivariate analysis, FIGO stage (P = 0.025) and EMA overexpression (P = 0.017) were independent prognostic factors for progression-free survival. Conclusions. EMA overexpression appears to be a marker of malignant transformation in the endometrium and it is an independent predictor of recurrent disease in endometrial cancer.

AB - Objective. The aim of this study was to analyze the value of epithelial membrane antigen (EMA) overexpression in benign and malignant endometrium and its prognostic significance. Methods. EMA immunostaining was performed in 178 paraffin-embedded specimens including 105 endometrial cancers, 40 endometrial hyperplasias, and 33 benign endometriums. EMA immunostaining was correlated with traditional prognostic factors and progression-free survival in endometrial cancer specimens. Results. EMA overexpression was observed more frequently in adenocarcinomas (60%) than in hyperplasias (15%) or benign endometrium (9.1%). EMA overexpression was observed in two patients with endometrial hyperplasia who progressed to carcinoma. In adenocarcinomas, EMA overexpression had a positive correlation with nonendometrioid subtypes (P = 0.012). In multivariate analysis, FIGO stage (P = 0.025) and EMA overexpression (P = 0.017) were independent prognostic factors for progression-free survival. Conclusions. EMA overexpression appears to be a marker of malignant transformation in the endometrium and it is an independent predictor of recurrent disease in endometrial cancer.

KW - Endometrial cancer

KW - Epithelial membrane antigen

KW - Prognostic factors

KW - Recurrence

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0034823963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034823963&partnerID=8YFLogxK

U2 - 10.1006/gyno.2001.6283

DO - 10.1006/gyno.2001.6283

M3 - Article

C2 - 11520144

AN - SCOPUS:0034823963

SN - 0090-8258

VL - 82

SP - 483

EP - 488

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 3

ER -

A comparison of epithelial membrane antigen overexpression in benign malignant endometrium

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this